The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | A Phase II trial evaluating CD19/CD22 bispecific CAR T-cell therapy in R/R DLBCL
In this video, Liang Wang, PhD, Beijing Tongren Hospital, Beijing, China, discusses the results of a Phase II trial (NCT06081478) investigating CD19/CD22 bispecific CAR T-cell therapy for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated impressive efficacy and a favourable safety profile in this patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
